CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Asia Pacific Leads The Way In Cell & Gene Therapy Trials

December 16, 2022

Asia Pacific Leads
Cell and gene therapies (CGTs) are continuing to gain momentum in life sciences globally. However, Asia Pacific (APAC) has demonstrated the most growth in CGT
developers of any other region, with a rise of 10% in
H1 2022 compared to 2021.1

Spotlight

High Purity New England

High Purity New England has grown from a small team of three people to a deeply experienced organization that employs over 200 professionals committed to advancing their customers' bioprocessing objectives from discovery to commercial launch. Their insight into the changing needs of the bioprocessing industry led to their state-of-the-art facility being the first in the Northeastern United States to receive ISO 9001:2015 certification for the specific application of design, development, manufacturing, and distribution of single-use assemblies.

OTHER WHITEPAPERS
news image

GMP Grade PMSF and Protease Inhibitors

whitePaper | February 23, 2023

Phenylmethylsulfonyl fluoride, better known as PMSF, is a small molecule serine protease inhibitor used to prevent unwanted proteolysis.

Read More
news image

Accelerating Global Access to Gene Therapies: Case Studies from Lowand Middle-Income Countries

whitePaper | October 18, 2022

This document is published by the World Economic Forum as a contribution to a project, insight area or interaction. The findings, interpretations and conclusions expressed herein are a result

Read More
news image

Early engagement and regulatory considerationsfor biotech

whitePaper | May 10, 2022

Biotechnology companies are at the epicenter of innovative drug development, with discoveries spanning from small molecules, large molecules, and biologics to genomic medicines

Read More
news image

Document quality control emerges as a discipline in its own right

whitePaper | November 19, 2022

Compiling a quality regulatory submission is a basic requirement for biopharmaceutical companies. Poor quality documents could lead to rejection of a regulatory application,

Read More
news image

Risk assessment of fungal materials

whitePaper | February 24, 2022

Sustainable fungal materials have a high potential to replace non-sustainable materials such as those used for packaging or as an alternative for leather and textile.

Read More
news image

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO).

Read More

Spotlight

High Purity New England

High Purity New England has grown from a small team of three people to a deeply experienced organization that employs over 200 professionals committed to advancing their customers' bioprocessing objectives from discovery to commercial launch. Their insight into the changing needs of the bioprocessing industry led to their state-of-the-art facility being the first in the Northeastern United States to receive ISO 9001:2015 certification for the specific application of design, development, manufacturing, and distribution of single-use assemblies.

Events